CN114133378B - Nilotinib hydrochloride eutectic and preparation method thereof - Google Patents

Nilotinib hydrochloride eutectic and preparation method thereof Download PDF

Info

Publication number
CN114133378B
CN114133378B CN202111024753.2A CN202111024753A CN114133378B CN 114133378 B CN114133378 B CN 114133378B CN 202111024753 A CN202111024753 A CN 202111024753A CN 114133378 B CN114133378 B CN 114133378B
Authority
CN
China
Prior art keywords
crystal
tartaric acid
nilotinib hydrochloride
nilotinib
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111024753.2A
Other languages
Chinese (zh)
Other versions
CN114133378A (en
Inventor
王磊鑫
谷慧科
王颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Qingmu Pharmaceutical Co ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Original Assignee
Sichuan Qingmu Pharmaceutical Co ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Qingmu Pharmaceutical Co ltd, Chengdu Easton Biopharmaceuticals Co Ltd filed Critical Sichuan Qingmu Pharmaceutical Co ltd
Publication of CN114133378A publication Critical patent/CN114133378A/en
Application granted granted Critical
Publication of CN114133378B publication Critical patent/CN114133378B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

The application relates to the field of drug crystal forms, in particular to nilotinib hydrochloride L-tartaric acid eutectic and a preparation method thereof. The nilotinib hydrochloride L-tartaric acid eutectic has the advantages of high solubility, high bioavailability, good stability, simple preparation method, environmental protection and good repeatability, and is suitable for large-scale industrial production.

Description

Nilotinib hydrochloride eutectic and preparation method thereof
Technical Field
The application belongs to the field of drug crystal forms, and particularly relates to nilotinib hydrochloride L-tartaric acid eutectic Form N and a preparation method thereof.
Background
Nilotinib hydrochloride (Nilotinib hydrochloride), chemical name: 4-methyl-N- [3- (4-methyl-1 hydro-imidazol-1-yl) -5- (trifluoromethyl) phenyl ] -3- [ (4-pyridin-3-ylpyrimidin-2-yl) amino ] benzamide monohydrochloride monohydrate, having the structure shown in (I):
nilotinib capsules were approved for use in the united states for the treatment of chronic granulocytic leukemia resistant to glibenclamide (imatinib) at day 10 and 29 of 2007. Nilotinib can bind to and stabilize the inactive conformation of the ABL protein kinase site. In vitro, nilotinib inhibited BCR-ABL kinase mediated proliferation of murine leukemia cell lines and proliferation of cell lines derived from ph+cml patients. Of the 33 mutations examined, nilotinib was able to overcome imatinib resistance caused by 32 BCR-ABL kinase mutations. Due to this biochemical activity nilotinib selectively inhibited BCR-ABL cell lines and philadelphia chromosome positive primary leukemia cell proliferation and induced apoptosis in all CML patients. But its solubility in water is only 0.2ug/ml, which is subjected to micronization treatment to increase the dissolution of the main drug substance in order to ensure bioavailability. However, the micronization process causes environmental pollution.
In patent WO2007015870, nilotinib hydrochloride form A, form A ', form A, "form B, form B', form S B Crystalline form S B 'form C, form C', form S C Form D, form S E And amorphous 13 crystalline forms. Form C is unstable in water and changes to form a, and forms a and B have low solubility in water, so that a form with high solubility and stability needs to be developed.
Disclosure of Invention
The application discloses a novel crystal Form N of nilotinib hydrochloride L-tartaric acid eutectic.
Nilotinib hydrochloride is shown in structural formula I:
l-tartaric acid is shown in a structural formula II:
the application provides nilotinib hydrochloride L-tartaric acid eutectic Form N, wherein an X-ray powder diffraction pattern of the eutectic is at a diffraction angle 2 theta: characteristic peaks are arranged at 10.38+/-0.2 degrees, 11.20+/-0.2 degrees, 13.36+/-0.2 degrees, 15.40+/-0.2 degrees, 18.12+/-0.2 degrees, 20.48+/-0.2 degrees, 21.72+/-0.2 degrees and 22.74 +/-0.2 degrees.
Preferably, the X-ray powder diffraction pattern of nilotinib hydrochloride L-tartaric acid co-crystal Form N is at diffraction angle 2θ: the characteristic peaks are included in the angles of 8.02+ -0.2 °, 10.38+ -0.2 °, 11.20+ -0.2 °, 12.58+ -0.2 °, 13.36+ -0.2 °, 14.18+ -0.2 °, 15.40+ -0.2 °, 16.00+ -0.2 °, 16.96+ -0.2 °, 18.12+ -0.2 °, 19.84+ -0.2 °, 20.48+ -0.2 °, 21.72+ -0.2 °,22.74 + -0.2 °, 24.06+ -0.2 °, 24.72+ -0.2 °, 25.76+ -0.2 °, 27.35+ -0.2 °, 28.28+ -0.2 °,36.28 + -0.2 °, and 38.38 + -0.2 °.
Preferably, the X-ray powder diffraction pattern of nilotinib hydrochloride L-tartaric acid co-crystal Form N is substantially as shown in FIG. 1.
Preferably, the nilotinib hydrochloride L-tartaric acid eutectic Form N differential scanning calorimeter spectrum has an endothermic peak at 196.44 ℃.
Preferably, the differential scanning calorimetric spectrum of nilotinib hydrochloride L-tartaric acid eutectic Form N is substantially as shown in figure 2.
Preferably, the thermogravimetric spectrum of nilotinib hydrochloride L-tartaric acid co-crystal Form N is substantially as shown in fig. 3.
Preferably, the nuclear magnetic spectrum of the nilotinib hydrochloride L-tartaric acid eutectic Form N is basically shown in fig. 4.
The application also provides a preparation method of the nilotinib hydrochloride L-tartaric acid eutectic Form N, which comprises the following steps:
dissolving nilotinib hydrochloride and L-tartaric acid in a solvent, stirring until crystals are separated out after the solution is clear, cooling, filtering and drying to obtain the nilotinib hydrochloride.
Preferably, the feeding mole ratio of nilotinib hydrochloride to L-tartaric acid is 1:1-3.
More preferably, the molar ratio of nilotinib hydrochloride to L-tartaric acid is 1:2.
Preferably, the solvent is methanol.
Preferably, the volume of the solvent is 10-30 times of the mass of nilotinib hydrochloride.
More preferably, the volume of solvent used is 20 times the mass of nilotinib hcl charge.
Preferably, the dissolution temperature is 30 ℃ to 60 ℃.
More preferably, the dissolution temperature is 50 ℃.
Preferably, the temperature is reduced to 0-20 ℃, and the filtration and the drying are carried out.
More preferably, the temperature is reduced to 15 ℃, and the mixture is filtered and dried.
The beneficial technical effects are as follows:
the application provides a novel nilotinib hydrochloride L-tartaric acid eutectic Form N, which has the advantages of high solubility, high bioavailability and good stability compared with the prior art.
The preparation method of the nilotinib hydrochloride L-tartaric acid eutectic Form N provided by the application is simple, environment-friendly, good in repeatability and suitable for large-scale industrial production.
Drawings
FIG. 1X-ray powder diffraction pattern of nilotinib hydrochloride L-tartaric acid co-crystal Form N
FIG. 2 differential scanning calorimetric map of nilotinib hydrochloride L-tartaric acid eutectic Form N
FIG. 3 thermogravimetric plot of nilotinib hydrochloride L-tartaric acid co-crystal Form N
FIG. 4 Nuclear magnetic resonance spectrum of nilotinib hydrochloride L-tartaric acid eutectic Form N
FIG. 5 XRD pattern of nilotinib hydrochloride L-tartaric acid co-crystal Form N stability experiment
FIG. 6 XRD pattern of nilotinib hydrochloride L-tartaric acid co-crystal Form I stability experiment
FIG. 7 XRD pattern of nilotinib hydrochloride L-tartaric acid co-crystal Form N acceleration stability test
FIG. 8 mean drug concentration versus time curve in plasma after single oral administration of female rats
Detailed Description
The present application will be described in further detail with reference to the following examples, which are only for illustrating the technical aspects of the present application and are not intended to limit the spirit and scope of the present application.
The terms used in the present application are explained as follows:
the term "co-crystal" means a composition of two or more phases; the phase refers to a substance having the same composition, crystal structure, and properties.
The term XRD refers to X-ray powder diffraction. In the application, the powder X-ray diffraction test instrument comprises: dandong metadx-2700B powder diffractometer; test conditions: cu K instrument ray, 40kV,40mA,3-40°。
the term DSC refers to a differential scanning calorimeter. Differential Scanning Calorimeter (DSC) as referred to in the present application: meltrele tolidol DSC1; test conditions: 25-250 ℃,10 ℃/min; n2 (50 mL/min).
The term TGA refers to thermogravimetric analyzer. In the present application, the thermogravimetric analyzer (TGA) is referred to: meltrele tolidol TGA2; test conditions: 30-250 ℃,10 ℃/min; n2 (50 mL/min).
In the application, the related nuclear magnetic resonance apparatus is Bruker; test conditions: 400MHz, deuterated DMSO as solvent, hydrogen spectrum.
In the context of the present application, the values of the diffraction angles 2theta (also known as 2theta or diffraction peaks) in the X-ray powder diffraction pattern are all in degrees (°).
When referring to a spectrum and/or data in a graph, the term "diffraction peak" refers to a feature that one skilled in the art would not attribute to background noise.
The crystal has an X-ray powder diffraction peak whose measure of 2theta or diffraction peak of the X-ray powder diffraction pattern has an experimental error, and the measure of 2theta or diffraction peak of the X-ray powder diffraction pattern may slightly differ between one machine and another machine and between one sample and another sample, and the value of the experimental error or difference may be +/-0.2 units or +/-0.1 units or +/-0.05 units, so that the value of the 2theta or diffraction peak cannot be regarded as absolute.
The differential scanning calorimetric curve (DSC) of the crystal has experimental errors, and the position and peak value of the endothermic peak may slightly differ between one machine and another machine and between one sample and another sample, and the experimental error or difference may have a value of 5 ℃ or less, or 4 ℃ or less, or 3 ℃ or less, or 2 ℃ or less, or 1 ℃ or less, so the peak position or peak value of the endothermic peak of the DSC cannot be regarded as absolute.
The thermogravimetric analysis curve (TGA) of the crystal has experimental errors, and the endothermic curve or the weight loss ratio may slightly differ between one machine and another machine and between one sample and another sample, and the experimental error or the difference may have a value of 0.004% or 0.003% or 0.002% or 0.001% or less, so the thermogravimetric analysis curve or the weight loss ratio thereof cannot be regarded as absolute.
Example 1
50mg of nilotinib hydrochloride and 15mg of L-tartaric acid are weighed and dissolved in 1ml of methanol at 50 ℃, the dissolved solution is continuously stirred until solid is separated out, the temperature is slowly reduced to 15 ℃, the stirring is continuously carried out for 24 hours at 15 ℃, filtration and vacuum drying are carried out, 26.5mg of light yellow solid is obtained, and the XRD pattern is shown in figure 1. The DSC pattern is shown in figure 2, the TGA pattern is shown in figure 3, and the nuclear magnetic pattern is shown in figure 4; the relevant data are shown in table 1.
TABLE 1
Example 2
200mg of nilotinib hydrochloride and 60mg of L-tartaric acid are weighed and dissolved in 4ml of methanol at 50 ℃, the dissolved solution is continuously stirred until solid is separated out, the temperature is slowly reduced to 15 ℃, the stirring is continuously carried out for 24 hours at 15 ℃, the filtration and the vacuum drying are carried out, 22.5mg of light yellow solid is obtained, and the XRD pattern is basically consistent with that of figure 1. The DSC, TGA and nuclear magnetic patterns are basically consistent with those of figures 2, 3 and 4 respectively.
Example 3
1.0g of nilotinib hydrochloride and 300mg of L-tartaric acid are weighed and dissolved in 20ml of methanol at 50 ℃, the solution is stirred continuously until solid is separated out, the temperature is slowly reduced to 15 ℃, the stirring is continued for 24 hours at 15 ℃, the filtration and the vacuum drying are carried out, and 0.55g of light yellow solid is obtained, and the XRD pattern is basically consistent with that of figure 1. The DSC, TGA and nuclear magnetic patterns are basically consistent with those of figures 2, 3 and 4 respectively.
Example 4
1.0g of nilotinib hydrochloride and 600mg of L-tartaric acid are weighed and dissolved in 20ml of methanol at 50 ℃, the solution is stirred continuously until solid is separated out, the temperature is slowly reduced to 15 ℃, the stirring is continued for 24 hours at 15 ℃, the filtration and the vacuum drying are carried out, and 0.74g of light yellow solid is obtained, and the XRD pattern is basically consistent with that of figure 1. The DSC, TGA and nuclear magnetic patterns are basically consistent with those of figures 2, 3 and 4 respectively.
Example 5
10.0g of nilotinib hydrochloride and 6.0g L-tartaric acid are weighed and dissolved in 200ml of methanol at 50 ℃, the solution is stirred continuously until solid is separated out after the solution is clear, the temperature is slowly reduced to 15 ℃, the stirring is continued for 24 hours at 15 ℃, the filtration and the vacuum drying are carried out, 7.6g of light yellow solid is obtained, and the XRD pattern is basically consistent with that of figure 1. The DSC, TGA and nuclear magnetic patterns are basically consistent with those of figures 2, 3 and 4 respectively.
Example 6
The equilibrium solubilities of nilotinib hydrochloride L-tartrate novel co-crystal Form N, nilotinib hydrochloride L-tartrate co-crystal Form I, nilotinib hydrochloride L-tartrate co-crystal Form II, form a, form B and Form C in water at 25 ℃ and 50 ℃ respectively were tested, with the results as shown in the following table:
the results show that nilotinib hydrochloride L-tartaric acid eutectic Form N has the largest solubility in water at 25 ℃ and 50 ℃ and has obvious solubility advantages.
Example 7
The nilotinib hydrochloride L-tartaric acid eutectic Form N is respectively placed under illumination and high temperature (60 ℃) for 20 days to carry out influence factor experiments, the crystal Form is not transformed, the XRD pattern is shown in figure 5, and the specific results are shown in the following table:
experimental conditions Days of placement Crystal form
High temperature (60 ℃ C.) For 20 days Nilotinib hydrochloride L-tartaric acid eutectic crystal
Illumination of For 20 days Nilotinib hydrochloride L-tartaric acid eutectic crystal
Example 8
The effect factor experiment is carried out by placing the nilotinib hydrochloride L-tartaric acid eutectic Form I at high humidity (RH 92.5%) and high temperature (60 ℃) for 15 days, and the experimental result shows that the nilotinib hydrochloride L-tartaric acid eutectic Form I is converted into nilotinib hydrochloride common crystal Form A under the high humidity condition, the crystal Form of the eutectic is unstable under the high humidity condition, and the XRD pattern is shown in figure 6.
EXAMPLE 9 nilotinib hydrochloride L-tartaric acid eutectic Form N accelerated stability test
And placing nilotinib hydrochloride L-tartaric acid eutectic Form N under the conditions of 25 ℃/RH 60% and 40 ℃/RH 75% respectively for 6 months for an acceleration stability experiment, wherein the experimental result shows that the novel eutectic Form N is stable in crystal Form, no crystal transformation occurs, and the XRD spectrum is shown in figure 7.
Test example in vivo pharmacokinetic test in rats
1. Purpose of test
Looking at the same dose, rats were given nilotinib L-tartrate co-crystals Form I, form II and Form N in a single oral administration and plasma nilotinib concentration levels and pharmacokinetic profile.
2. Materials and methods
2.1, test agent
Nilotinib hydrochloride L-tartaric acid co-crystal Form I, supplied by the division of research on crystalline forms of the division of biological pharmaceutical Co., ltd., lot number B-20255-31-05;
nilotinib hydrochloride L-tartaric acid co-crystal Form II, supplied by the division of research on crystalline forms of the division of biological pharmaceutical Co., ltd., lot number B-20255-31-06;
nilotinib hydrochloride L-tartaric acid new eutectic Form N, supplied by the division of research on crystalline forms of the division of biological pharmacy, inc. of Complanatoside, lot number C-19233-74-02;
2.2 test animals
SD rats, females, weighing 220-240g, purchased from Chengdu Ensvier Biotechnology Inc. as a substitute from Hunan Style reaches laboratory animals Inc., license number: SCXK (Hunan) 2019-0004.
2.3 test methods
The test drug was formulated into a uniform suspension of 1.25mg/kg with corn oil, immediately administered orally to rats at a volume of 4mL/kg, and 0.1mL of blood was taken from the jugular vein 15min, 30min, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 24h before and after administration, placed in EDTA-K2 tube, centrifuged for 10min, plasma was isolated, and frozen at-80 ℃.
2.4, LC/MS biological sample analysis:
mixing 50 μl of blood plasma with 5 μl of working solution or blank diluent, adding 150 μl of acetonitrile precipitant containing internal standard, vortex shaking for 2min, centrifuging 12000r/min for 10min, collecting supernatant 2 μl and 200 μl of pure water: after acetonitrile (1:1) was mixed, the samples were taken at a volume of 3. Mu.L for analysis.
2.5, test results:
animal experiments were performed on nilotinib hydrochloride L-tartaric acid co-crystals Form I, form II and Form N, respectively, i.e. the average concentration of API (ng-mL-1) in plasma at different times after single oral administration to female rats, and the results are shown in fig. 8 as the average drug concentration-time curve in plasma after single oral administration to female rats, and the main pharmacokinetic parameters are shown in the following table:
parameters (parameters) Form I Form II Form N
T 1/2 (h) 8.99±5.24 3.06±0.79 6.21±4.07
T max (h) 4.67±2.31 4.67±1.15 6.00±2.00
C max (ng·mL -1 ) 1050±345 2013±1541 2350.00±760.99
AUC last (h·ng·mL -1 ) 13687±4196 12101±5288 30298.51±7532.21
Cl_F_obs(mL/hr/kg) 1236±182 1832±658 606.17±77.16
MRT(h) 8.59±1.88 5.80±1.08 8.10±1.25
Experimental results show that the AUC of the nilotinib hydrochloride L-tartaric acid new eutectic Form N last AUC greater than FormI and FormII last I.e. the total amount absorbed into the blood circulation is much higher than for Form I and Form II, and thus Form N has a higher bioavailability than for Form I and Form II, which is advantageous.
It will be apparent to those skilled in the art that various modifications and variations can be made in the compounds of the present application and the process for preparing them without departing from the spirit or scope of the application, and thus the scope of the application encompasses numerous modifications and variations as come within the scope of the claims and their equivalents.

Claims (9)

1. Nilotinib hcl L-tartaric acid co-crystal Form N, characterized by an X-ray powder diffraction pattern of the co-crystal at diffraction angle 2Θ: characteristic peaks are arranged at 10.38+/-0.2 degrees, 11.20+/-0.2 degrees, 13.36+/-0.2 degrees, 15.40+/-0.2 degrees, 18.12+/-0.2 degrees, 20.48+/-0.2 degrees, 21.72+/-0.2 degrees and 22.74 +/-0.2 degrees.
2. The co-crystal of claim 1, wherein the X-ray powder diffraction pattern of the co-crystal is at diffraction angle 2Θ: the characteristic peaks are included in the angles of 8.02+ -0.2 °, 10.38+ -0.2 °, 11.20+ -0.2 °, 12.58+ -0.2 °, 13.36+ -0.2 °, 14.18+ -0.2 °, 15.40+ -0.2 °, 16.00+ -0.2 °, 16.96+ -0.2 °, 18.12+ -0.2 °, 19.84+ -0.2 °, 20.48+ -0.2 °, 21.72+ -0.2 °,22.74 + -0.2 °, 24.06+ -0.2 °, 24.72+ -0.2 °, 25.76+ -0.2 °, 27.35+ -0.2 °, 28.28+ -0.2 °,36.28 + -0.2 °, and 38.38 + -0.2 °.
3. The co-crystal of claim 1, wherein the co-crystal has an X-ray powder diffraction pattern as shown in figure 1.
4. A co-crystal according to any one of claims 1 to 3, characterized in that the differential scanning calorimetry pattern of the co-crystal has an endothermic peak at 196.44 ℃.
5. A co-crystal according to any one of claims 1-3, characterized in that the differential scanning calorimetry pattern of the co-crystal is shown in figure 2.
6. A co-crystal according to any one of claims 1-3, characterized in that the thermal weight spectrum of the co-crystal is shown in figure 3.
7. A co-crystal according to any one of claims 1 to 3, wherein the co-crystal has a nuclear magnetic profile as shown in figure 4.
8. A process for the preparation of nilotinib hcl L-tartaric acid co-crystals according to claim 1, characterized in that it comprises: dissolving nilotinib hydrochloride and L-tartaric acid in a solvent, stirring until crystals are precipitated after the nilotinib hydrochloride and the L-tartaric acid are dissolved, cooling, filtering and drying to obtain the nilotinib hydrochloride and L-tartaric acid, wherein the feeding molar ratio of the nilotinib hydrochloride to the L-tartaric acid is 1:1-3; the solvent is methanol; the volume of the solvent is 10-30 ml/g of the mass of nilotinib hydrochloride; the dissolution temperature is 30-60 ℃; cooling to 0-20 ℃.
9. The preparation method according to claim 8, wherein the molar ratio of nilotinib hydrochloride to L-tartaric acid is 1:2; the volume of the solvent is 20ml/g of the mass of nilotinib hydrochloride; the dissolution temperature is 50 ℃, and the temperature is reduced to 15 ℃.
CN202111024753.2A 2020-09-04 2021-09-02 Nilotinib hydrochloride eutectic and preparation method thereof Active CN114133378B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020109198738 2020-09-04
CN202010919873 2020-09-04

Publications (2)

Publication Number Publication Date
CN114133378A CN114133378A (en) 2022-03-04
CN114133378B true CN114133378B (en) 2023-08-15

Family

ID=80393873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111024753.2A Active CN114133378B (en) 2020-09-04 2021-09-02 Nilotinib hydrochloride eutectic and preparation method thereof

Country Status (1)

Country Link
CN (1) CN114133378B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (en) * 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA
GT200600316A (en) * 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
EP3430004B1 (en) * 2016-03-14 2020-07-15 Pliva Hrvatska D.O.O. Solid state forms of nilotinib salts

Also Published As

Publication number Publication date
CN114133378A (en) 2022-03-04

Similar Documents

Publication Publication Date Title
EP2571863B1 (en) Nilotinib salts and crystalline forms thereof
US20180155291A1 (en) New crystal form of lenvatinib methanesulfonate salt and preparation method thereof
CN113473991A (en) GABAASalts and crystalline forms of positive allosteric modulators
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
TWI820223B (en) Crystal forms of morpholinoquinazoline compounds, their preparation methods and applications
CN110483486B (en) Crystal form of oxtinib ketorolac and preparation method thereof
CN112142679B (en) Gefitinib and vanilloid eutectic methanol solvate and preparation method thereof
JP6851572B2 (en) Crystal form of hydrogen sulfate of JAK kinase inhibitor and its production method
US11124517B2 (en) Crystal form of Baricitinib and preparation method thereof
JP2023553021A (en) Salts of pyrrolopyrimidine compounds, their crystals and their uses
CN114133378B (en) Nilotinib hydrochloride eutectic and preparation method thereof
WO2020244612A1 (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
CN114539161B (en) Olaparib-urea eutectic and preparation method thereof
CN111205290B (en) Crystal form of JAK kinase inhibitor and preparation method thereof
JP6965274B2 (en) Amine solvate of sodium-glucose bond transporter inhibitor, its preparation method and its application
US10233144B2 (en) Crystalline form of AHU377, preparation method and use thereof
EP4204405A1 (en) Polymorphs of an ssao inhibitor
CN115215797B (en) Novel crystal form of cabozitinib malate and preparation method thereof
AU2018298154B2 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
US20060194833A1 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
BR112017028492B1 (en) (4-((3R,4R)-3-METHOXITETRA-HYDRO-PYRAN-4- YLAMINO)PIPERIDIN-1-YL) CITRATE (5- METHYL-6-(((2R, 6S)-6-(P- TOLIL) TETRA-HYDRO-2H-PIRAN-2-IL)METHYLAMINO)PYRIMIDIN-4-IL) METHANONE, ITS USE AND ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION
US20190218184A1 (en) Novel Crystalline Form of Lenvantinib Mesylate and Process of Preparation Thereof
CN110964017A (en) Polymorph of Ribociclib monosuccinate and preparation method and application thereof
WO2024067085A1 (en) Citrate salt of cyclin-dependent kinase (cdk4/6) inhibitor, crystal form thereof, preparation method therefor and use thereof
CN112110865A (en) Isonicotinamide acipimox cocrystal II and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant